Crossject (ALCJ.PA) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Supplies · France · ISIN FR0011716265

Price
1.27 EUR
Market cap
76.78 m EUR
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
212.74 %
Return on assets (ROA)
-34.07 %

Crossject financials

Fiscal year20242025
Revenue4.12 m EUR0.00 EUR
Gross profit-21.89 m EUR-22.38 m EUR
Operating income-15.24 m EUR-12.10 m EUR
EBIT-14.19 m EUR-12.10 m EUR
Net income-12.80 m EUR-10.37 m EUR
Diluted EPS – continuing operations-0.28 EUR-0.20 EUR

Full history since 2010, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Crossject

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.